Check for updates

OPEN ACCESS

EDITED BY Pedro L. Mangabeira-Albernaz, Hospital Israelita Albert Einstein, Brazil

REVIEWED BY Yi-Jun Ge, Anhui Medical University, China Bharatendu Chandra, The University of Iowa, United States

*CORRESPONDENCE Erzhen Chen ⊠ chenerzhen@hotmail.com Ying Zhou ⊠ zy12941@rjh.com.cn

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 06 May 2024 ACCEPTED 05 July 2024 PUBLISHED 26 July 2024

CITATION

Shi R, Wang Y, Chen Y, Yang Z, Jing F, Shang H, Chen E and Zhou Y (2024) Age-specific disparity in insomnia among COVID-19 patients in Fangcang shelter hospitals: a population-based study in Shanghai, China. *Front. Neurol.* 15:1420898. doi: 10.3389/fneur.2024.1420898

COPYRIGHT

© 2024 Shi, Wang, Chen, Yang, Jing, Shang, Chen and Zhou. This is an open-access article distributed under the terms of the **Creative Commons Attribution License** (**CC BY**). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Age-specific disparity in insomnia among COVID-19 patients in Fangcang shelter hospitals: a population-based study in Shanghai, China

Ruizi Shi^{1†}, Yihui Wang^{2†}, Ying Chen², Zhitao Yang^{2,3}, Feng Jing⁴, Hanbing Shang^{5,6}, Erzhen Chen^{1,2}* and Ying Zhou¹*

¹Shanghai Institute of Aviation Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Division of Medical Affairs, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁴Nursing Department, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁵Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁶Department of Neurosurgery, Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁶Department of Neurosurgery, Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁶Department, China

Background: Fangcang shelter hospitals are quarantine facilities offering primary medical treatment for mild and asymptomatic SARS-CoV-2 cases. Little is known about the age-specific prevalence of insomnia among patients in Fangcang shelter hospitals, particularly in older age groups.

Methods: This cross-sectional study was conducted in the three largest Fangcang shelter hospitals during the lockdown period, from March to May 2022, in Shanghai. The patients' demographic and medical information was recorded. Insomnia was defined according to the prescriptions for zolpidem and estazolam. The overall and age-specific prevalence and the risk factors of insomnia were investigated through regression models.

Results: A total of 2,39,448 patients were included in this study (59.09% of the patients were male, the median age was 42, and 73.41% of the patients were asymptomatic), with the prevalence of insomnia being 3.1%. The prevalence of insomnia varied across different age groups (<18 years: 0.23%, 18–64 years: 2.64%, and ≥65 years: 10.36%). SARS-CoV-2 vaccine, regardless of the number of doses, was significantly associated with a decreased risk of insomnia for the group aged ≥65 years. Three doses of the vaccine reduced the risk of insomnia for patients aged 18–64 years. An extra day in the hospital significantly increased the risk of insomnia by approximately 10% for all age groups. Mild symptoms were significantly associated with a higher risk of insomnia among patients aged <65 years old, while being male and residing in the surrounding area were negatively associated with insomnia for all adults.

Conclusion: This study observed that older patients were a high-risk population for developing insomnia in Fangcang shelter hospitals. SARS-CoV-2 vaccination might decrease the risk of insomnia in adults, especially the older adult, which indicates the benefits of vaccination for reducing insomnia among infected patients.

KEYWORDS

insomnia, Fangcang shelter hospital, SARS-CoV-2, age differences, SARS coronavirus, vaccine

1 Introduction

Since December 2019, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been spreading throughout the world. Since traditional approaches were limited regarding curbing the disaster caused by this infectious disease, Fangcang shelter hospitals, characterized by their rapid construction, massive scale, and low building and operation costs that make them particularly well suited to address public health emergencies, were developed in many cities of China to admit massive numbers of patients for treatment (1, 2). Therefore, in late February 2022, when an outbreak of the Omicron wave of the COVID-19 pandemic hit Shanghai (3), numerous SARS-CoV-2-infected residents in Shanghai were isolated and treated in Fangcang shelter hospitals (4), which were once again improved to be a critical measure for patient care and pandemic control in the following months (5).

Several investigations have demonstrated a strong correlation between coronavirus and sleep disorders. A previous meta-analysis estimated and reported an increased prevalence of insomnia during and after the severe coronavirus outbreak in 2019 (6). Some studies used self-reported questionnaires to assess and report sleep problems during the COVID-19 pandemic (7, 8). More recently, a study examining the sleep quality of participants during the COVID-19 transmission wave since December 7, 2022, using the online questionnaire, the Pittsburgh Sleep Quality Index (PSQI), found that 36.8% of participants reported poor sleep quality (9). However, these studies did not focus on patients in Fangcang shelter hospitals. Several studies suggested that SARS-CoV-2-infected patients in Fangcang shelter hospitals were prone to sleep disorders due to continuous bright light even at night, the lack of personal space, environmental noises, attitude toward infection, and prognosis, as well as dysfunctional beliefs about sleep (10-13). Gu et al. (14) reported that 14.8% of healthcare workers experienced insomnia in a Jianghan Fangcang shelter hospital from February 21 to February 28, 2020. However, the sleep problems of healthcare workers might be different from the patients' due to their role in Fangcang shelter hospitals. Moreover, different SARS-CoV-2 variants showed varied impacts on the severity of clinical symptoms, outcomes, and related health problems.

Numerous mutations in the spike protein of the Omicron variant increased its transmissibility and allowed for viral escape by evading the immune response. The variant generated false negative results in polymerase chain reaction assays due to "S gene target failure" (15, 16). One of the characteristics of the Omicron variant was that it caused quick spreading of COVID-19 infection with massively mild and asymptomatic carriers (17). A single-center cross-sectional study reported that 34.3% of asymptomatic COVID-19 carriers in a Fangcang shelter hospital were observed to have poor sleep quality. This was assessed using the PSQI from March 2022 to April 2022 (18). Another study reported that approximately 3.6% of patients admitted to Fangcang shelter hospitals in Shanghai used associated psychiatric drugs, and more than half of the patients used psychiatric drugs to treat insomnia (19). To the best of our knowledge, however, there has been limited research on the physiological effects of COVID-19 infection on insomnia across different age groups during the Omicron wave.

Different risk factors could affect the sleep health of people at different ages as sleep health varies widely across the lifespan. This was especially evident in Fangcang shelter hospitals during the late period of the COVID-19 pandemic. It is crucial to understand the sleep issues experienced by patients belonging to different age groups during the COVID-19 pandemic in Fangcang shelter hospitals for managing and meeting the needs of patients during any future outbreaks and for carrying out prompt interventions for vulnerable groups. We conducted a multicenter exploratory study to investigate the age-specific prevalence and risk factors of insomnia among COVID-19 patients during the Omicron wave in the three largest Fangcang shelter hospitals in Shanghai. The specific goals of the study included the following: (1) characterization of all asymptomatic and mild COVID-19 patients in Fangcang shelter hospitals; (2) identification of the age-specific prevalence of insomnia; and (3) investigation of the risk factors associated with insomnia among COVID-19 patients in Fangcang shelter hospitals.

2 Methods

2.1 Study design and enrollment

This multicenter, cross-sectional study was conducted in three of six provincial-level Fangcang shelter hospitals in Shanghai, China, including the National Exhibition and Convention Centre (NECC) in Qingpu district, the Shanghai New International Expo Centre (SNIEC) in Pudong district, and the World Expo Museum (WEM) in Huangpu district.

The National Exhibition and Convention Centre was the largest Fangcang shelter hospital, which received 1,69,922 infected patients from 26 March 2022 to 31 May 2022. The Shanghai New International Expo Centre was the first provincial-level Fangcang shelter hospital with a bed capacity of more than 10,000 beds. A total of 46,695 infected patients were admitted from 9 April 2022 to 3 May 2022. The World Expo Museum was the first huge Fangcang shelter hospital to complete the admission task, with a total of 25,647 SARS-CoV-2infected patients cured from 26 March to 25 May 2022 (Supplementary Table S1).

All patients received physical evaluations, but only those who were diagnosed as asymptomatic or with mild symptoms were eventually admitted to Fangcang shelter hospitals. Fangcang shelter hospitals provide primary medical services, including health management, medical observation, and targeted treatment, combined with traditional Chinese medical care, to help patients recover and be discharged. The exclusion criteria included the following: patients who provided missing or obviously incorrect information and patients who had a self-reported history of psychiatric disorders. This study was approved by the Institutional Review Board (IRB) of Ruijin Hospital, affiliated with the Shanghai Jiao Tong University School of Medicine, and all methods were carried out in accordance with the approved guidelines.

Abbreviations: SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; COVID-19, Coronavirus disease 2019; NECC, National Exhibition and Convention Centre; SNIEC, Shanghai New International Expo Centre.

2.2 Assessment of outcomes

Patients' demographic and medical information was recorded in Fangcang shelter hospitals. We collected all information about the prescription medications of participants during their stay at the Fangcang shelter hospitals. All information about the psychiatric medications prescribed to COVID-19 patients is provided in a list in Supplementary Table S2. In this study, we followed the approach of a previous study where insomnia was defined as a condition that required a prescription for zolpidem and estazolam in consideration of their clinical application (19). Zolpidem is a short-acting non-benzodiazepine sleeping pill that is frequently used as the first line of treatment for individuals with episodic or incipient insomnia. Estazolam is a long-acting benzodiazepine sleeping drug, also known as sulazepam, with a variety of effects. Thus, it is frequently used in the treatment of moderate, severe, and chronic insomnia, and it can also treat sleep disturbances induced by aberrant emotions such as worry, despair, and stress. It is not feasible to diagnose insomnia in a timely manner using ICSD-D and DSM-5 criteria or using any other sleep problem scales because of the limited number of healthcare workers and the large number of patients to be treated.

2.3 Measurement and data collection

Demographic data were recorded in the information system of Fangcang shelter hospitals, namely age $(0-17, 18-64, and \ge 65 \text{ years})$, sex (male or female), marital status (single, married, and others), place of residence (central districts and surrounding areas), doses of vaccine (none, one or two, and more than two), discharge diagnosis (asymptomatic and mild symptoms), and the length of hospital stay. Central districts in Shanghai included the Huangpu district, Xuhui district, Changning district, Yangpu district, Jing'an district, Hongkou district, and Putuo district. Other districts, besides central districts, were categorized as surrounding areas. Asymptomatic and mild infection of SARS-CoV-2 was defined according to the Chinese Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Version 9). The category of mild infections included patients without dyspnea and with a decrease in oxygen saturation, progressive symptoms, pneumonia signs in chest imaging, or the need for escalation of medical care. Patients without any symptoms were defined as asymptomatic. The length of hospital stay was defined as the date of discharge minus the date of admission to Fangcang shelter hospitals.

2.4 Statistical analysis

Data analysis was performed using Stata 15.0. Continuous data were presented as mean (\pm standard deviation, SD) or median (interquartile range, IQR); group comparisons were assessed by conducting student's *t*-test and the Kruskal–Wallis test, as appropriate. Categorical data were tabulated as numbers and percentages and assessed by conducting the chi-squared (χ^2) test. The overall and age-specific prevalence of insomnia was calculated. We performed multivariate regression analysis to calculate the adjusted odds ratio (aOR) of correlates associated with insomnia. We constructed the interaction between age and all other correlates to see if there was any age-specific effect of the correlates on insomnia. We then put each interaction term into regression models individually to obtain the *p*-value for each interaction. There was only one interaction per model. In addition to age, potential explanatory variables that were examined in the multivariate regression model included sex, vaccination status, marital status, being diagnosed with a mild infection, the location of shelter hospitals, case resource, and the length of hospital stay. Therefore, we ran models that included all participants and were stratified by three age groups. In the three age-specific models, age was also included as a continuous variable. A *p*-value of <0.05 was considered statistically significant.

3 Results

3.1 Characteristics of participants

A total of 2,42,264 patients were hospitalized in the three largest Fangcang shelter hospitals between 26 March 2022 and 31 May 2022. According to the inclusion and exclusion criteria, a total of 2,39,448 cases were included in the final analysis after 2,816 patients with missing or incorrect information were excluded (Figure 1). Table 1 summarizes the demographic characteristics of the study population. The median age of the participants was 42 (IQR:30–54) years, with a higher proportion of male-to-female participants (59.09% vs. 40.91%). A total of 52.63% of SARS-CoV-2 infected patients were from the surrounding areas of Shanghai, 73.41% were asymptomatic, and 42.68% had three doses of the vaccine. The median time of the length of hospital stay was 7.0 (IQR: 5.0–10.0) days. People aged <18, 18–64, and \geq 65 years made up 4.72, 87.41, and 7.87% of the participants, respectively.

The characteristics of the participants from different age groups were significantly different. Those aged \geq 65 years had the lowest proportion of male participants (52.77%), the highest proportion of participants with missing vaccinations (40.68%), were diagnosed with mild infection (27.76%), and had the longest duration of stay in the Fangcang shelter hospitals. In contrast, those aged<18 years had the lowest proportion of receiving three doses of the vaccine (1.84%) and had mild infection (21.29%) (Table 1). Differences between the age groups could also be observed regarding comorbidities, including hypertension, diabetes, heart disease, kidney disease, arrhythmia, coronary artery disease (CAD), heart failure, stroke, and thrombotic diseases (Figure 2).

3.2 Prevalence and correlates of insomnia

The prevalence of insomnia was 3.13% overall and increased by age groups (<18 years: 0.23%, as a reference in the regression model; 18–64 years: 2.64%, aOR=10.11, 95% CI: 6.91–14.81; \geq 65 years: 10.36%, aOR=32.64, 95% CI: 22.23–47.92). Women and those who came from central districts had a significantly higher prevalence of insomnia. The prevalence of insomnia for the unvaccinated, one- or two-dose, and three-dose groups was 4.15, 2.71, and 2.95%, respectively, with an aOR of 0.85 (95% CI: 0.80–0.90) for the one- or two-dose group and an aOR of 0.84 (95% CI: 0.80–0.89) for the three-dose group. Patients with mild symptoms had a higher prevalence of insomnia, with an aOR of 1.09 (95% CI:1.04–1.15). Regarding the



location of Fangcang shelter hospitals, patients in NECC had the highest prevalence of insomnia (3.63%). It was observed that an extra day in the hospital significantly increased the risk of insomnia by 12% (aOR = 1.12, 95% CI: 1.11-1.13, and p < 0.001) (Table 2).

3.3 Age-specific prevalence and correlates of insomnia

The frequency of insomnia that increased with age groups could be observed among subgroups based on all demographic characteristics (all p < 0.001) (Table 3). When categorized by age groups, insomnia exhibited distinct patterns in different groups. No significant difference in the prevalence of insomnia was observed among participants with different sexes, marital status, number of vaccine doses, and residence places in the group that included participants aged <18 years. Participants with mild symptoms who stayed in the NECC had a higher prevalence of insomnia. A significantly lower prevalence of insomnia was observed in the group that included 18-64 years old, male, unmarried, vaccinated, and asymptomatic patients, and residents of surrounding areas. In the group that included patients aged ≥ 65 years, male patients, vaccinated patients, surrounding area residents, and those who were treated in the WEM, a significantly lower prevalence of insomnia was observed, while no significant difference was observed between asymptomatic patients and patients with mild symptoms (Table 3).

Figure 3 shows the results of the multivariate regression analysis for the three age groups. In the group aged <18 years, age (aOR = 1.12, 95% CI: 1.00-1.24), mild symptoms (aOR = 2.23, 95% CI: 1.00-4.93), and a longer stay in the hospital (aOR = 1.10, 95%CI: 1.00–1.20 per day) were significantly associated with a higher risk of insomnia. In the group aged 18-64 years, being male (aOR = 0.71, 95% CI: 0.67-0.75), age (aOR = 1.04, 95% CI: 1.03-1.04), mild symptoms (aOR = 1.16, 95% CI: 1.10-1.23), and an extra day of staying in the hospital (aOR = 1.12, 95% CI: 1.12-1.13) were positively associated with insomnia. In addition to being treated in two other Fangcang shelter hospitals compared with the NECC, living in surrounding areas and vaccination were negatively associated with the risk of insomnia. In particular, only vaccination in three doses (aOR=0.88, 95% CI: 0.82-0.94) had a significant association with insomnia. In the group aged \geq 65 years, being male (aOR = 0.83, 95% CI: 0.76-0.92) and an extra day of staying in the hospital (aOR = 1.08, 95% CI: 1.07-1.09) were positively associated with a higher risk of insomnia. While vaccination, mild symptoms, being treated in the WEM, and living in surrounding areas were negatively associated with the risk of insomnia. One or two doses (aOR = 0.87, 95% CI: 0.77-0.98) and three doses (aOR = 0.87, 95% CI: 0.78-0.98) were significantly associated with a lower risk of insomnia (Figure 3).

Variable	Overall, N (%)	Age groups			<i>p</i> -value
		<18 years <i>N</i> (%)	18–64 years N (%)	≥65 years <i>N</i> (%)	
Total, <i>n</i>	239,482 (100)	11,305 (100)	209,328 (100)	18,849 (100)	
Age, median (IQR)	42 (30–54)	10 (7–14)	41 (31–52)	68 (66–70)	<0.001
Sex					<0.001
Female	97,956 (40.91)	4,912 (43.45)	84,144 (40.20)	8,900 (47.23)	
Male	141,492 (59.09)	6,393 (56.55)	125,155 (59.80)	9,944 (52.77)	
Marital status					<0.001
Unmarried	88,154 (36.82)	11,102 (98.20)	74,135 (35.42)	2,917 (15.48)	
Married	143,409 (59.89)	0 (0.00)	128,616 (61.45)	14,793 (78.50)	
Others	7,885 (3.29)	203 (1.80)	6,548 (3.13)	1,134 (6.02)	
Place of residence					<0.001
Central districts	113,434 (47.37)	5,773 (51.07)	96,001 (45.87)	11,660 (61.88)	
Surrounding areas	126,014 (52.63)	5,532 (48.93)	113,298 (54.13)	7,184 (38.12)	
Number of vaccine doses					<0.001
None	54,169 (22.95)	4,369 (38.76)	42,197 (20.48)	7,603 (40.68)	
One or two	81,122 (34.37)	6,697 (59.41)	69,505 (33.73)	4,920 (26.32)	
Three	100,748 (42.68)	207 (1.84)	94,372 (45.8)	6,169 (33)	
Discharge diagnosis					<0.001
Mild	175,778 (73.41)	8,898 (78.71)	153,267 (73.23)	13,613 (72.24)	
Asymptomatic	63,670 (26.59)	2,407 (21.29)	56,032 (26.77)	5,231 (27.76)	
Location of Fangcang shelter hospitals					<0.001
NECC	167,367 (69.90)	7,100 (62.80)	146,718 (70.10)	13,549 (71.90)	
WEM	25,593 (10.69)	1,122 (9.92)	23,131 (11.05)	1,340 (7.11)	
SNIEC	46,488 (19.41)	3,083 (27.27)	39,450 (18.85)	3,955 (20.99)	
Length of hospital stay, median (IQR)	7.0 (5.0–10.0)	7.0 (5.0–9.7)	7.0 (5.0–10.0)	8.0 (5.5–11.0)	<0.001

TABLE 1 Characteristics of COVID-19 patients in Fangcang shelter hospitals.

Central districts in Shanghai included the Huangpu district, Xuhui district, Changning district, Yangpu district, Jing'an district, Hongkou district, and Putuo district. Surrounding areas indicated other districts excluding central districts. NECC, National Exhibition and Convention Center; WEM, World Expo Museum; SNIEC, Shanghai New International Expo Centre. Texts in bold type indicate statistical significance.

4 Discussion

To the best of our knowledge, this is the first large-scale study that investigated the age-specific prevalence and correlates of insomnia among patients infected with SARS-COV-2, who were admitted to Fangcang shelter hospitals based on prescription drug records during the period of the Omicron wave from 26 March 2022 to 31 May 2022. We investigated 2,39,448 patients in three Fangcang shelter hospitals, namely the NECC, the WEM, and the SNIEC. Our results showed that the prevalence of insomnia increased with age and was 0.23, 2.64, 10.36, and 3.13% for the groups aged <18 years, 18–64 years, \geq 65 years, and overall, respectively. Vaccination was found to be associated with a reduced risk of insomnia for adults, especially for those aged \geq 65 years.

In Spain, 75.2% of the general population had sleep problems during the lockdown (20). In France, 56% of the population had poorer sleep quality, 48% had less regular sleep schedules, 30% slept less, and 33% slept more during the lockdown (21). Among COVID-19 inpatients in China, the prevalence of insomnia was 42.8% (22). Our study evaluated the prevalence of insomnia during

the late period of the pandemic. Previous studies have investigated sleep problems using self-reported questionnaires (8, 20, 21, 23). According to the criteria of insomnia based on medication prescription in this study, the overall prevalence of insomnia during the late period of the pandemic was 3.1%.

In our study, the prevalence of insomnia was observed to be the highest in the group aged \geq 65 years, with a nearly 31 times higher risk of insomnia than the group aged <18 years and a three times higher risk than the group aged 18–64 years. A recent study reported that in recent years, Americans who were 65 years of age or older experienced a larger increase in the prevalence of trouble sleeping than the other two younger age groups, whereas when compared to the middle-aged group (24), they experienced a similar prevalence of trouble sleeping. All these studies shared a common observation, which was that sleep problems were less frequent among young people. It has been acknowledged that older adults do not sleep as well as younger adults because changes occur as we grow older in both the macro-level architecture of sleep, such as sleep length and phases, and the micro-level architecture of sleep, such as the amount and quality of sleep oscillations (25). Against the background of the



SARS-COV-2 pandemic, continuous bright light, even at night, and environmental noises may accelerate insomnia among older adults who are prone to sleep problems.

Our study reported that the SARS-COV-2 vaccine was significantly associated with the risk reduction of insomnia in adult patients. The homeostatic regulation of physiological sleep can be regulated by the immune system through the release of regulatory substances such as the cytokines tumor necrosis factor and interleukin caused by acute or chronic immune activation (26). A previous study showed that patients with mild symptoms had lower levels of inflammation and a higher level of neutralizing antibodies (27). Therefore, vaccination may make a significant contribution to sleep homeostasis in the context of infectious diseases. This might also explain the phenomenon that asymptomatic patients had a lower prevalence of insomnia because of their lower inflammation levels. Moreover, as stress and worries are considered important factors that disturb falling asleep or the quality of sleep (28), vaccinated patients may have fewer worries about their health status, and therefore, have fewer sleep problems. Receiving the first dose of the COVID-19 vaccine led to significant improvements in mental health among US adults. Another study conducted in the US also showed that COVID-19 vaccination was significantly associated with declines in the level of distress and perceived risks of infection among adults (29). Similarly, a shortterm improvement in depressive and anxiety symptoms was observed among Swedish adults who received COVID-19 vaccination during the pandemic (30). In this study, 40.7% of people aged \geq 65 years did not take the SARS-COV-2 vaccine, which may have partially accelerated their worries about their health status when staying in the open ward of Fangcang shelter hospitals (31). No significant association between vaccination and insomnia was observed among the participants of the group aged <18 years, which might be due to their immune system or psychological state. Interestingly, only three doses of vaccine had a significant

TABLE 2 Risk factors of insomnia among COVID-19 patients.

Variable	Prevalence (cases/ participants, ‰)	aOR	<i>p</i> -value	p for interaction with age groups				
Total	3.13 (7,501/239,448)	_	_	—				
Age groups, years								
<18	0.23 (26/11,305)	Reference		_				
18-64	2.64 (5,522/209,299)	10.71 (6.63–17.3)	<0.001	_				
≥65	10.36 (1,953/18,844)	30.36 (18.73-49.24)	<0.001	_				
Sex								
Female	3.81 (3,727/97,956)	Reference		$p_{(18-64 \text{ years} \times \text{male})} = 0.090$				
Male	2.67 (3,774/141,492)	0.88 (0.83-0.94)	<0.001	$p_{(\geq 65 \text{ years} \times \text{male})} = 0.185$				
Marital status	I	I	1	I				
Unmarried	2.20 (1,940/88,154)	Reference		$p_{(18-64 \text{ years} \times \text{married})} < 0.001$				
Married	3.64 (5,219/143,409)	1.12 (1.05–1.20)	<0.001	$p_{(18-64 \text{ years} \times \text{ others})} = 0.251$				
Others	4.34 (342/7,885)	1.22 (1.05-1.42)	<0.001					
Number of vaccine doses								
None	4.15 (2,250/54,169)	Reference		$p_{(18-64 \text{ years} \times 1-2 \text{ doses})} = 0.024$				
One or two	2.71 (2,196/81,122)	0.91 (0.84-0.98)	<0.001	$p_{(\geq 65 \text{ years} \times 1 \sim 2 \text{ doses})} = 0.034$				
				$p_{(18-64 \text{ years } \times 3 \text{ doses})} = 0.148$				
Three	2.95 (2,975/100,748)	0.91 (0.85–0.98)	<0.001	$p_{(\geq 65 \text{ years} \times 3 \text{ doses})} = 0.166$				
Discharge diagnosis								
Asymptomatic	2.86 (5,026/175,778)	Reference		$p_{(18-64 \text{ years} \times \text{mild})} = 0.080$				
Mild	3.89 (2,475/63,670)	1.09 (1.04–1.15)	0.001	$p_{(\geq 65 \text{ years} \times \text{mild})} = 0.006$				
Location of Fangcang shelter hospitals								
NECC	3.63 (6,077/167,367)	Reference		$p_{(18-64 \text{ years} \times \text{WEM})} = 0.699$				
WEM	1.70 (435/25,593)	0.05 (0.04-0.07)	<0.001	$p_{(18-64 \text{ years} \times \text{SNIEC})} = 0.334$				
				$p_{(18-64 \text{ years} \times \text{WEM})} = 0.496$				
SNIEC	2.13 (989/46,488)	0.39 (0.35-0.43)	<0.001	$p_{(\geq 65 \text{ years} \times \text{SNIEC})} = 0.021$				
Place of residence								
Central districts	4.25 (4,820/113,434)	Reference		$p_{(18-64 \text{ years} \times \text{ surrounding areas})} = 0.974$				
Surrounding areas	2.13 (2,681/126,014)	0.56 (0.53–0.60)	<0.001	$p_{(\geq 65 \text{ years} \times \text{surrounding areas})} = 0.476$				
Length of hospital stay	_	1.12 (1.11–1.13)	<0.001	$p_{(18-64 \text{ years} \times \text{ length of hospital stay})} = 0.602$				
				$p_{(\geq 65 \text{ years} \times \text{ length of hospital stay})} = 0.662$				

aOR, adjusted odds ratio. Central districts in Shanghai included the Huangpu district, Xuhui district, Changning district, Yangpu district, Jing'an district, Hongkou district, and Putuo district. Surrounding areas indicated other districts excluding central districts. NECC, National Exhibition and Convention Center; WEM, World Expo Museum; SNIEC, Shanghai New International Expo Centre. Texts in bold type indicate statistical significance.

association with a reduced risk of insomnia for the group aged 18–64 years. Contrarily, vaccination, regardless of the number of doses, decreased the risk of insomnia for the group aged \geq 65 years. This result highlighted the importance and benefit of a vaccine promotion program for the older adult. Future research could further investigate whether vaccines have an influence on insomnia through some physiological mechanisms.

We found that women were more likely to have a higher risk of insomnia; this finding agreed with another study on Chinese inpatients (22). However, a previous study found no significant association between sex and insomnia among COVID-19 patients, who experienced sleep disturbances 2 months after discharge from the hospital (32). Another study on US adults suggested that the prevalence of trouble sleeping and prescription medications for insomnia was higher in women, while the prevalence of short sleep duration and sleep disorders was higher in men (33), which suggested a more complicated sex-specific difference regarding sleep problems. The increased prevalence of sleep disorders during the COVID-19 pandemic has also been highlighted, which may be due to isolation, quarantine, financial loss, and other psychosocial factors (34). Therefore, the result of our study might suggest that women were prone to infectious disease disasters and highlight the importance of psychological intervention for vulnerable populations. Other distinct age-specific correlates of insomnia were also observed in this study. In the middle-aged group, marriage was significantly associated with a lower risk of insomnia, while this correlation was not observed in the group aged \geq 65 years. This might have been caused by other complex socio-psychological factors that might need to be further explored. TABLE 3 Age-specific prevalence of insomnia among COVID-19 patients.

Variable	Age groups			<i>p</i> -value				
	<18 years	18–64 years	\geq 65 years					
Sex								
Female	0.18 (9/4,903)	3.24 (2,728/81,416)	11.12 (990/7,910)	<0.001				
Male	0.27 (17/6,376)	2.23 (2,794/122,361)	9.68 (963/8,981)	<0.001				
<i>p</i> -value	0.363	<0.001	0.001					
Marital status								
Unmarried	0.23 (26/11,076)	2.16 (1,604/72,531)	10.63 (310/2,607)	<0.001				
Married	0 (0/0)	2.89 (3,717/124,899)	10.15 (1,502/13,291)	<0.001				
Others	0 (0/203)	3.07 (201/6,347)	12.43 (141/993)	<0.001				
<i>p</i> -value	0.49	<0.001	0.046					
Number of vaccine doses								
None	0.11 (5/4,364)	3.23 (1,363/40,834)	11.6 (882/6,721)	<0.001				
One or two	0.3 (20/6,677)	2.46 (1,711/67,794)	9.45 (465/4,455)	<0.001				
Three	0.48 (1/206)	2.53 (2,385/91,987)	9.55 (589/5,580)	<0.001				
<i>p</i> -value	0.106	<0.001	<0.001					
Discharge diagnosis								
Asymptomatic	0.16 (14/8,884)	2.35 (3,606/149,661)	10.33 (1,406/12,207)	<0.001				
Mild	0.5 (12/2,395)	3.42 (1,916/54,116)	10.46 (547/4,684)	<0.001				
<i>p</i> -value	0.002	<0.001	0.795					
Location of Fangcang shelter hospitals								
NECC	0.32 (23/7,077)	3.15 (4,623/142,095)	10.56 (1,431/12,118)	<0.001				
WEM	0.09 (1/1,121)	1.52 (352/22,779)	6.12 (82/1,258)	<0.001				
SNIEC	0.06 (2/3,081)	1.39 (547/38,903)	11.13 (440/3,515)	<0.001				
<i>p</i> -value	0.025	<0.001	<0.001					
Place of residence								
Central districts	0.29 (17/5,756)	3.59 (3,447/92,554)	11.63 (1,356/10,304)	<0.001				
Surrounding areas	0.16 (9/5,523)	1.83 (2,075/111,223)	8.31 (597/6,587)	<0.001				
<i>p</i> -value	0.144	<0.001	<0.001					

Central districts in Shanghai included the Huangpu district, Xuhui district, Changning district, Yangpu district, Jing'an district, Hongkou district, and Putuo district. Surrounding areas indicated other districts excluding central districts. NECC, National Exhibition and Convention Center; WEM, World Expo Museum; SNIEC, Shanghai New International Expo Centre. Texts in bold type indicate statistical significance.

There are some limitations to this study. First, although the prevalence of insomnia was assessed using prescribed medication, it was not measured using ICSD-D and DSM-5 criteria, actigraphy and polysomnography, or any other sleep scales; it depended on the subjective medical needs of infected patients to some extent. Our study did not include the proportion of patients who had less severe insomnia and did not have medications. A stricter criterion for evaluating insomnia in this study could have led to a lower frequency of insomnia problems, as it has been previously reported that the number of people who experience trouble sleeping is far greater than that of those who use medications commonly prescribed for insomnia (33). However, electronic medical records are the most convenient and precise tools for such a large-scale study. We also showed the detailed prevalence of insomnia defined by two medications (Supplementary Table S4). Second, all patients included had mild symptoms or were asymptomatic patients who were infected during the period when Omicron was prevalent. Since severe respiratory diseases might affect sleep, the results generated from this study might not be generalizable to all populations.

Third, we did not have records of previous insomnia history for patients in Fangcang shelter hospitals or the medical care service provided at different study periods; these need to be further explored. However, to avoid ascertainment bias as much as possible, we excluded patients with a self-reported history of psychiatric disorders. Finally, this was a crosssectional study. Hence, it could not assess temporality or causation between factors of interest and the development of insomnia.

5 Conclusion

In conclusion, our findings suggested that the prevalence and risk factors of insomnia differed in different age groups, with older people being a high-risk population. Vaccination was beneficial to reduce the risk of insomnia in adults, especially the older adult. More attention should be paid to vulnerable subpopulations, such as women, unvaccinated individuals, those who are single, those residing in central districts, and those who stayed at Fangcang shelter hospitals



Risk factors of insomnia categorized by age groups among COVID-19 patients aOR, adjusted odds ratio. Central districts in Shanghai included the Huangpu district, Xuhui district, Changning district, Yangpu district, Jing'an district, Hongkou district, and Putuo district. Surrounding areas indicated other districts excluding central districts. NECC, National Exhibition and Convention Center; WEM, World Expo Museum; SNIEC, Shanghai New International Expo Centre.

for a long time. In addition, a comprehensive approach might strengthen interventions related to the mental health impact caused by the pandemic. different age groups when quarantined in Fangcang shelter hospitals during the late period of the pandemic remains unclear.

What is already known on this topic

There is sufficient evidence for the occurrence of sleep problems among various subpopulations during the early stage of the COVID-19 pandemic. However, the evidence for sleep problems is based almost entirely on self-reported questionnaires. In addition, most epidemiological studies were also performed among patients infected with Alpha and Delta variants, both of which showed different features from the Omicron variant. Moreover, Fangcang shelter hospitals are characterized by the high volume of patient admissions, open wards, and adaption to the requirement of treatments. Patients admitted to Fangcang shelter hospitals might exhibit different characteristics in sleep problems. We updated the search using PubMed from 2019 until 31 October 2023, for the keywords "insomnia," "COVID-19," and "Fangcang shelter hospital" to specify the quarantine places where patients stayed and identified only seven relevant studies. Five of the seven studies were performed when the pandemic was dominated by Alpha and Delta variants, and the other two studies investigated sleep or mental health problems among SARS-CoV-2-infected patients using non-probability sampling. No age-specific issues were investigated in consideration of the age-dependent changes in sleep. In summary, the prevalence and risk factors of insomnia (e.g., the effect of vaccination, the size of Fangcang shelter hospitals, and the length of hospital stay) among

What this study adds

This large-scale study is the first to investigate the age-specific prevalence of insomnia among Omicron-infected patients admitted to Fangcang shelter hospitals. Based on prescription medication records, we investigated the prevalence of insomnia among Omicron-infected patients, most of whom were asymptomatic. The prevalence of insomnia was relatively low compared to the study conducted in the pre-Omicron period, and insomnia was most prevalent among patients \geq 65 years. This study also provided evidence for the effect of vaccination on insomnia: in an age-specific regression model, three doses of vaccine were observed to be significantly associated with a reduced risk of insomnia for patients aged 18–64 years, while vaccination regardless of the number of doses was significantly associated with a reduced risk of insomnia for patients aged \geq 65 years. Moreover, patients admitted to smaller Fangcang shelter hospitals had a lower prevalence of insomnia, and an extra day in the hospital significantly increased the risk of insomnia for all age groups.

How this study might affect research, practice, or policy

During the period of the Omicron wave, all individuals infected with the Omicron variant were admitted to Fangcang shelter hospitals. This epidemiological study provided evidence for the age-specific prevalence and risk factors of insomnia among patients with mild symptoms and asymptomatic SARS-CoV-2 infected patients in Fangcang shelter hospitals. With the older adult being a high-risk population for insomnia, they would benefit from the intervention of a SARS-CoV-2 vaccine program for both physical and physiological reasons. Individuals belonging to different age groups are prone to insomnia due to various factors, which highlights the importance of age-oriented treatment and care. Intervention on the delayed impact of the pandemic on insomnia holds great potential to support both sleep health goals and combat infectious diseases. This finding is especially important in terms of interventions for sleep problems in situations where infectious diseases break out and a large number of patients gather in places such as Fangcang shelter hospitals..

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by the Institutional Review Board (IRB) of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin.

Author contributions

RS: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review & editing. YW: Conceptualization, Investigation, Resources, Writing – review & editing, Data curation. YC: Investigation, Methodology, Resources, Writing – review & editing. ZY: Investigation, Project administration, Writing – review & editing. FJ: Project administration, Supervision, Writing – review & editing. HS: Project administration, Writing – review & editing. HS: Project administration, Writing – review & editing. Validation, Project administration, Resources, Supervision, Validation, Writing – review & editing. YZ: Conceptualization, Data

References

1. Fang D, Pan S, Li Z, Yuan T, Jiang B, Gan D, et al. Large-scale public venues as medical emergency sites in disasters: lessons from COVID-19 and the use of Fangcang shelter hospitals in Wuhan, China. *BMJ Glob Health.* (2020) 5:e002815. doi: 10.1136/bmjgh-2020-002815

2. Chen S, Zhang Z, Yang J, Wang J, Zhai X, Bärnighausen T, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. *Lancet*. (2020) 395:1305–14. doi: 10.1016/S0140-6736(20)30744-3

3. Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic. *Lancet.* (2022) 399:2011–2. doi: 10.1016/S0140-6736(22)00838-8

4. Zhu J, Zhu GP, Weng YM, Zhang Y, Li BX. Clinical practice and effectiveness analysis of the management of corona virus disease 2019 infected at Shanghai Fangcang

curation, Funding acquisition, Methodology, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors sincerely appreciate the support of all participants in this study. This work was supported by the National Natural Science Foundation of China (Grant Nos. 82103945 and 82270087), the Program for Outstanding Medical Academic Leader, Shanghai Shenkang Hospital Development Center of China (Grant Nos. SHDC2020CR1028B, SHDC22021304, and SHDC2202201), and the Youth Cultivation Foundation of Ruijin Hospital (Grant No. KY20240282).

Acknowledgments

The authors thank the healthcare workers of and patients admitted to Fangcang shelter hospitals for their dedication and contribution to the research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1420898/ full#supplementary-material

shelter hospital: a descriptive study. Risk Manag Healthc Policy. (2023) 16:337-46. doi: 10.2147/RMHP.S403414

5. Ye L, Li WF, Shao J, Xu Z, Ju J, Xu H. Fighting omicron epidemic in China: realworld big data from Fangcang shelter hospital during the outbreak in Shanghai 2022. *J Infect.* (2022) 85:436–80. doi: 10.1016/j.jinf.2022.07.006

6. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry*. (2020) 7:611–27. doi: 10.1016/S2215-0366(20)30203-0

7. Ahmed GK, Khedr EM, Hamad DA, Meshref TS, Hashem MM, Aly MM. Long term impact of COVID-19 infection on sleep and mental health: a cross-sectional study. *Psychiatry Res.* (2021) 305:114243. doi: 10.1016/j.psychres.2021.114243

8. Deng J, Zhou F, Hou W, Silver Z, Wong CY, Chang O, et al. The prevalence of depressive symptoms, anxiety symptoms and sleep disturbance in higher education students during the COVID-19 pandemic: a systematic review and meta-analysis. *Psychiatry Res.* (2021) 301:113863. doi: 10.1016/j.psychres.2021.113863

9. Liu X, Liu M, Ai G, Hu N, Liu W, Lai C, et al. Sleep and mental health during the COVID-19 pandemic: findings from an online questionnaire survey in China. *Front Neurol.* (2024) 15:1396673. doi: 10.3389/fneur.2024.1396673

 Abel KM, Carr MJ, Ashcroft DM, Chalder T, Chew-Graham CA, Hope H, et al. Association of SARS-CoV-2 infection with psychological distress, psychotropic prescribing, fatigue, and sleep problems among UK primary care patients. *JAMA Netw Open.* (2021) 4:e2134803. doi: 10.1001/jamanetworkopen.2021.34803

11. Gu Y, Zhu Y, Xu F, Xi J, Xu G. Factors associated with mental health outcomes among patients with COVID-19 treated in the Fangcang shelter hospital in China. *Asia Pac Psychiatry*. (2021) 13:e12443. doi: 10.1111/appy.12443

12. Peng J, Zhang T, Li Y, Wu L, Peng X, Li C, et al. Effects of dysfunctional beliefs about sleep on sleep quality and mental health among patients with COVID-19 treated in Fangcang shelter hospitals. *Front Public Health*. (2023) 11:1129322. doi: 10.3389/fpubh.2023.1129322

13. Zhong Y, Zhao H, Lee TY, Yu T, Liu MF, Ji J. Experiences of COVID-19 patients in a Fangcang shelter hospital in China during the first wave of the COVID-19 pandemic: a qualitative descriptive study. *BMJ Open*. (2022) 12:e065799. doi: 10.1136/ bmjopen-2022-065799

14. Gu Y, Zhu Y, Xu G. Factors associated with mental health outcomes among health care workers in the Fangcang shelter hospital in China. *Int J Soc Psychiatry*. (2022) 68:64–72. doi: 10.1177/0020764020975805

15. Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. *J Med Virol.* (2022) 94:1825–32. doi: 10.1002/jmv.27588

16. Zhang J, Tang W, Gao H, Lavine CL, Shi W, Peng H, et al. Structural and functional characteristics of the SARS-CoV-2 omicron subvariant BA.2 spike protein. *Nat Struct Mol Biol.* (2023) 30:980–90. doi: 10.1038/s41594-023-01023-6

17. Yu W, Guo Y, Zhang S, Kong Y, Shen Z, Zhang J. Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: a systematic review and analysis. *J Med Virol.* (2022) 94:5790–801. doi: 10.1002/jmv.28066

18. Xu L, Gao Y, Shi D, Wang Y, Li R, Cai Y. Social support moderates the relationship between sleep quality and mental health: a Chinese Fangcang shelter hospital-based study in asymptomatic COVID-19 carriers. *Heliyon*. (2024) 10:e31782. doi: 10.1016/j. heliyon.2024.e31782

19. Yu P, Bian X, Xie Z, Wang X, Zhang X, Gu Z, et al. Risk factor analysis of omicron patients with mental health problems in the Fangcang shelter hospital based on psychiatric drug intervention during the COVID-19 pandemic in Shanghai, China. *Front Psychiatry*. (2023) 14:1100849. doi: 10.3389/fpsyt.2023.1100849

20. Martínez-de-Quel Ó, Suárez-Iglesias D, López-Flores M, Pérez CA. Physical activity, dietary habits and sleep quality before and during COVID-19 lockdown: a longitudinal study. *Appetite.* (2021) 158:105019. doi: 10.1016/j.appet.2020.105019

21. Bertrand L, Schröder C, Bourgin P, Maruani J, Atoui Y, d'Ortho MP, et al. Sleep and circadian rhythm characteristics in individuals from the general population during the French COVID-19 full lockdown. *J Sleep Res.* (2022) 31:e13480. doi: 10.1111/jsr.13480

22. Wang Y, Zhu LY, Ma YF, Bo HX, Deng HB, Cao J, et al. Association of insomnia disorder with sociodemographic factors and poor mental health in COVID-19 inpatients in China. *Sleep Med.* (2020) 75:282–6. doi: 10.1016/j.sleep.2020.06.011

23. Barrea L, Pugliese G, Framondi L, di Matteo R, Laudisio D, Savastano S, et al. Does SARS-CoV-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index. *J Transl Med.* (2020) 18:318. doi: 10.1186/s12967-020-02465-y

24. Wang S, Rossheim ME, Nandy RR. Trends in prevalence of short sleep duration and trouble sleeping among US adults, 2005–2018. *Sleep*. (2023) 46:zsac231. doi: 10.1093/sleep/zsac231

25. Mander BA, Winer JR, Walker MP. Sleep and human aging. *Neuron.* (2017) 94:19-36. doi: 10.1016/j.neuron.2017.02.004

26. Besedovsky L, Lange T, Haack M. The sleep-immune crosstalk in health and disease. *Physiol Rev.* (2019) 99:1325–80. doi: 10.1152/physrev.00010.2018

27. Xiao N, Nie M, Pang H, Wang B, Hu J, Meng X, et al. Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. *Nat Commun.* (2021) 12:1618. doi: 10.1038/ s41467-021-21907-9

28. Lei Z, Qiongjing Y, Qiuli W, Sabrina K, Xiaojing L, Changli W. Sleep quality and sleep disturbing factors of inpatients in a Chinese general hospital. *J Clin Nurs*. (2009) 18:2521–9. doi: 10.1111/j.1365-2702.2009.02846.x

29. Koltai J, Raifman J, Bor J, McKee M, Stuckler D. COVID-19 vaccination and mental health: a difference-in-difference analysis of the understanding America study. *Am J Prev Med.* (2022) 62:679–87. doi: 10.1016/j.amepre.2021.11.006

30. Chourpiliadis C, Lovik A, Kähler AK, Valdimarsdóttir UA, Frans EM, Nyberg F, et al. Short-term improvement of mental health after a COVID-19 vaccination. *PLoS One.* (2023) 18:e0280587. doi: 10.1371/journal.pone.0280587

31. Wright L, Steptoe A, Fancourt D. Are adversities and worries during the COVID-19 pandemic related to sleep quality? Longitudinal analyses of 46,000 UK adults. *PLoS One*. (2021) 16:e0248919. doi: 10.1371/journal.pone.0248919

32. Islam MK, Molla MMA, Hasan P, Sharif MM, Hossain FS, Amin MR, et al. Persistence of sleep disturbance among post-COVID patients: findings from a 2-month follow-up study in a Bangladeshi cohort. *J Med Virol.* (2022) 94:971–8. doi: 10.1002/jmv.27397

33. Zuo L, Chen X, Liu M, Dong S, Chen L, Li G, et al. Gender differences in the prevalence of and trends in sleep patterns and prescription medications for insomnia among US adults, 2005 to 2018. *Sleep Health*. (2022) 8:691–700. doi: 10.1016/j. sleh.2022.07.004

34. Partinen M. Sleep research in 2020: COVID-19-related sleep disorders. Lancet Neurol. (2021) 20:15–7. doi: 10.1016/S1474-4422(20)30456-7